What drove the pre-market move in 8K7.SI stock on Feb 12 2026?

The pre-market uptick to **S$0.093** followed the Feb 11 earnings announcement and higher-than-average volume **723,200**. Market focus is on revenue growth, inventory days and cash conversion as drivers for 8K7.SI stock movement.

What is Meyka AI's short-term forecast for 8K7.SI stock?

Meyka AI projects a monthly target near **S$0.10** and a yearly projection **S$0.1047**, implying about **+12.63%** potential upside from S$0.093. Forecasts are model estimates and not guarantees.

What are the main financial risks for 8K7.SI stock investors?

Major risks include negative trailing EPS **-0.01**, long inventory days **215**, slow receivables **120 DSO**, and negative operating cash flow per share **-0.00766**, which pressure liquidity and margins for 8K7.SI stock.

How does UG Healthcare compare with its healthcare peers on valuation?

UG Healthcare shows a low price-to-book **0.37** versus sector average PB **1.72**, and a negative PE versus sector PE **22.3**, indicating a valuation discount tied to weaker profitability for 8K7.SI stock.

SG Stocks

S$0.093 pre-market: UG Healthcare (8K7.SI, SES) Feb 12 2026 earnings insight

ByHuzaifa Zahoor February 11, 2026February 11, 2026

UG Healthcare (8K7.SI) trades at S$0.093 in pre-market on 12 Feb 2026 after the company filed earnings on 11 Feb. The 8K7.SI stock reaction was modest: a +2.20% intraday move on volume 723,200 versus average 570,342. Investors will focus on working capital metrics, margins and Meyka AI model forecasts after a year low of S$0.09 and a year high of S$0.124. This earnings spotlight summarises the key financials, technicals, Meyka AI grade and near-term price targets for 8K7.SI stock.